IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.240
-0.040 (-3.13%)
Mar 28, 2025, 4:00 PM EDT - Market closed
IGM Biosciences Revenue
In the year 2024, IGM Biosciences had annual revenue of $2.68M with 25.77% growth. IGM Biosciences had revenue of $412.00K in the quarter ending December 31, 2024, a decrease of -36.71%.
Revenue (ttm)
$2.68M
Revenue Growth
+25.77%
P/S Ratio
28.01
Revenue / Employee
$17,980
Employees
149
Market Cap
74.12M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIGMS News
- 2 months ago - IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out - Market Watch
- 2 months ago - IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs - GlobeNewsWire
- 5 months ago - IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - IGM Biosciences to Present at Three Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay - Market Watch
- 6 months ago - IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO - Benzinga
- 6 months ago - IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases - Barrons
- 6 months ago - IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga